RxDoctor Payments Data

Anastasie Dunn-Pirio, MD

Neurology · San Diego, CANPI 1700177136

Payments from drug & device makers

$3,049in general payments, 2019–2025

Across 34 payments — averaging $89.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$2K
  • Amgen$226
  • AbbVie$162
  • Lilly USA, LLC$98
  • Novartis$85
  • Biogen$44
  • plus $139 from 6 others

What the payments were for

  • Consulting fees$2,29575%
  • Speaking & faculty fees$231%
  • Food & beverage$73124%

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,049 in reported general payments places this provider in the 55th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$62,461
Medicare patients
227
Services billed
468

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MayzentSiponimod15$212,600
Glatiramer Acetate11$34,420
Nurtec OdtRimegepant Sulfate12$25,886
KeppraLevetiracetam13$20,928
Aimovig AutoinjectorErenumab-Aooe20$14,220
FingolimodFingolimod Hcl17$7,391
Oxcarbazepine20$3,464
Levetiracetam40$2,740
Baclofen57$1,522
Gabapentin69$1,216
Lacosamide14$1,128
Pregabalin28$845
Modafinil15$788
Duloxetine Hcl14$475
Lamotrigine22$448

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisMayzent$85$212,60015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,996 neurology providers in California.

Other neurology in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →